According to emerging evidence, pneumococcal conjugate vaccines (PCVs) not only prevent pneumococcal disease but also have the potential to indirectly reduce viral respiratory tract infections (RTIs) by affecting pneumococcal-viral interactions.
Researchers recently performed a systematic review of interventional and observational studies published between 2000 and 2022 on vaccine efficacy/adjusted effectiveness (VE) and the overall effect of PCV7, PCV9, PCV10, or PCV13 against viral RTI.